Major Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
Arbli™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually
COMMACK, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formulary of three (3) leading U.S. pediatric academic medical centers and hospitals specializing in the treatment of children with complex and chronic medical conditions.
The formulary additions represent an important commercial milestone for Arbli™ and expands the product’s presence within the institutional and pediatric healthcare market. Arbli™ is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric and other patient populations with difficulty swallowing tablets.
Arbli™ addresses a large and established U.S. losartan market representing approximately $219 million in sales and approximately 72 million prescriptions annually (IQVIA MAT Apr 2026). By eliminating the variability and inconvenience associated with pharmacy compounding, Scienture believes that Arbli™ provides healthcare professionals with a consistent, convenient and scalable ready-to-use treatment option.
Arbli™ is indicated for the treatment of hypertension in adults and pediatric patients six years of age and older. Its ready-to-use 10 mg/mL oral suspension provides flexible dosing without the need for extemporaneous pharmacy compounding, attributes that are particularly relevant in pediatric care, where patients may require individualized dosing or have difficulty swallowing conventional tablets.
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture, commented, “The commercial rollout of Arbli™ has continued to gain momentum, with wholesale orders increasing sequentially and adoption expanding across key healthcare channels. These formulary additions represent an important growth milestone in the commercialization of Arbli™ and, importantly, its adoption within the pediatric healthcare setting, where the product provides much needed patient benefits. With the U.S. losartan market representing approximately $219 million in sales annually, even modest market penetration could represent a meaningful commercial opportunity for Arbli™. The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as we continue to expand Arbli™’s market penetration. We believe the combination of expanding institutional adoption, increasing wholesale orders and a highly attractive market opportunity provides a strong foundation for continued growth.”
“We believe this is just the beginning of the opportunity for Arbli™ within the pediatric hospital market,” added Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture. “We believe the addition of Arbli™ by leading pediatric academic medical centers can help support our efforts to expand adoption across other institutions. We remain focused on building broader hospital and institutional access while continuing to expand payer coverage, pharmacy availability and distribution nationwide.”
The new formulary placements build upon Scienture’s broader commercialization strategy for Arbli™, which is focused on expanding commercial and government payer coverage, pharmacy availability, institutional adoption and distribution access. The Company intends to continue pursuing hospital and institutional formulary opportunities, including within pediatric healthcare settings, as it works to broaden Arbli™ adoption and increase patient access nationwide.
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR